
Influenza A viruses and SARS-CoV-2 cause global health problems. Establishes factors involved in viral replication, antiviral defence or inflammation are considered attractive targets for pharmaceutical treatment strategies. We will design tailor-made nanoparticles for compounds with limited cell-permeation. We will use an available and highly scalable synthetic antiviral drug, a natural anti-inflammatory drug, or inhibitors for viral uptake and viral uncoating. These nanoparticles will be characterized for their functionality in cellular systems.
Grafik Projekt D02
Graphic: B. Löffler/C. Hoffmann/C. EhrhardtProf. Dr. Christina Ehrhardt
Image: Michael Szabo, UKJProf. Dr. Christina Ehrhardt
Experimental Virology Section
Institute of Medical Microbiology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
Phone: + 49 3641 9 395 701
Christina.Ehrhardt@med.uni-jena.de
Prof. Dr. Carsten Hoffmann
Image: Michael Szabo, UKJProf. Dr. Carsten Hoffmann
Institute for Molecular Cell Biology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
Phone: + 49 3641 9 395 600
carsten.Hoffmann@med.uni-jena.de
Dr. Stephanie Schubert
Image: Dr. Stephanie SchubertDr. Stephanie Schubert
Institute of Pharmacy (IP)
Friedrich Schiller University Jena
Lessingstrasse 8
07743 Jena
Phone: +49 3641 9-48599
stephanie.schubert@uni-jena.de
Laura Klement
Image: Laura KlementLaura Klement
Institute for Molecular Cell Biology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
laura.klement@uni-jena.de